| AD | Anxiety/depression-related module |
| AMP | Adenosine monophosphate |
| BZD | Benzodiazepine |
| CORT | Corticosterone |
| DA | Dopamine |
| DPA | Docosapentaenoic acid |
| EEG | Electroencephalography |
| EMG | Electromyography |
| ESI | Electrospray ionization |
| FC | Fold change |
| GABA | γ-Aminobutyric acid |
| Glu | Glutamate |
| Gln | Glutamine |
| HRMS | High-resolution mass spectrometry |
| JYF | Panax quinquefolius-containing herbal extract |
| KEGG | Kyoto Encyclopedia of Genes and Genomes |
| L-DOPA | 3,4-Dihydroxyphenylalanine |
| mTOR | Mammalian target of rapamycin |
| NE | Norepinephrine |
| NREM | Non-rapid eye movement |
| NREMS | Non-rapid eye movement sleep |
| OPLS-DA | Orthogonal partial least squares discriminant analysis |
| OXA | Orexin A |
| PCA | Principal component analysis |
| PFA | Paraformaldehyde |
| PPI | Protein–protein interaction |
| QC | Quality control |
| REM | Rapid eye movement |
| REMS | Rapid eye movement sleep |
| S | Sleep disorder-related module |
| SWD | Spike-wave discharge |
| TCA cycle | Tricarboxylic acid cycle |
| VIP | Variable importance in projection |
| W | Withdrawal syndrome-related module |
| WAD | Withdrawal–anxiety/depression shared module |
| WADS | Withdrawal–anxiety/depression–sleep disorder common module |
| WS | Withdrawal–sleep disorder shared module |